Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: The role of folate pharmacogenetics

Journal of Clinical Psychopharmacology

Volumn 32, Issue 2, 2012, Pages 261-265

  Ellingrod, Vicki L ^a,b   Taylor, Stephan F ^b   Dalack, Gregory ^b   Grove, Tyler B ^a,b   Bly, Michael J ^a   Brook, Robert D ^c   Zöllner, Sebastian K ^a,c   Pop Busui, Rodica ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Antipsychotics; Bipolar disorder; Folate; Metabolic syndrome; Schizophrenia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CATECHOL METHYLTRANSFERASE; CLOZAPINE; FOLIC ACID; GENOMIC DNA; HOMOCYSTEINE; METHIONINE; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; VALINE; VALPROIC ACID;

ADULT; ALLELE; AMINO ACID BLOOD LEVEL; ARTICLE; BIPOLAR DISORDER; BODY MASS; BODY WEIGHT; CIGARETTE SMOKING; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FOLIC ACID BLOOD LEVEL; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PHARMACOGENETICS; POLYPHARMACY; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; SCHIZOPHRENIA; SEX DIFFERENCE; SIDE EFFECT; TREATMENT DURATION;

ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CATECHOL O-METHYLTRANSFERASE; CROSS-SECTIONAL STUDIES; FEMALE; FOLIC ACID; GENETIC VARIATION; HOMOCYSTEINE; HUMANS; LIFE STYLE; MALE; METABOLIC SYNDROME X; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PHARMACOGENETICS; RISK FACTORS; SCHIZOPHRENIA; SMOKING;

EID: 84857911892     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182485888     Document Type: Article

References (29)

1. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19-32. (Pubitemid 41587460)
2. Davidson MH. A symposium: National Cholesterol Education Program Adult Treatment Panel III: impact and implementation of the new guidelines. Introduction. Am J Cardiol. 2002;89:1C-2C.
3. Gade W, Schmit J, Collins M, et al. Beyond obesity: the diagnosis and pathophysiology of metabolic syndrome. Clin Lab Sci. 2010;23:62-65, 51, 61; quiz.
4. De Hert M, Schreurs V, Vancampfort D, et al. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009;8:15-22.
5. Ellingrod VL, Miller DD, Taylor SF, et al. Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophr Res. 2008;98:47-54. (Pubitemid 350235903)
6. Kim YI. 5,10-Methylenetetrahydrofolate reductase polymorphisms and pharmacogenetics: a new role of single nucleotide polymorphisms in the folate metabolic pathway in human health and disease. Nutr Rev. 2005;63:398-407.
7. Frankenburg FR. The role of one-carbon metabolism in schizophrenia and depression. Harv Rev Psychiatry. 2007;15:146-160. (Pubitemid 47237771)
8. Klerk M, Verhoef P, Clarke R, et al. MTHFR 677CY9T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002;288:2023-2031. (Pubitemid 35204693)
9. Garcia-Miss Mdel R, Perez-Mutul J, Lopez-Canul B, et al. Folate, homocysteine, interleukin-6, and tumor necrosis factor alfa levels, but not the methylenetetrahydrofolate reductase C677T polymorphism, are risk factors for schizophrenia. J Psychiatr Res. 2010;44:441-446.
10. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565-575. (Pubitemid 38500310)
11. Henderson DC, Copeland PM, Borba CP, et al. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry. 2006;67:789-797. (Pubitemid 43946186)
12. Schneede J, Refsum H, Ueland PM. Biological and environmental determinants of plasma homocysteine. Semin Thromb Hemost. 2000;26:263-279.
13. Petronijevic ND, Radonjic NV, Ivkovic MD, et al. Plasma homocysteine levels in young male patients in the exacerbation and remission phase of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1921-1926.
14. Tunbridge EM, Harrison PJ, Warden DR, et al. Polymorphisms in the catechol-O-methyltransferase (COMT) gene influence plasma total homocysteine levels. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:996-999.
15. Allen NC, Bagade S, McQueen MB, et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet. 2008;40:827-834. (Pubitemid 351913655)
16. Barnett JH, Jones PB, Robbins TW, et al. Effects of the catechol-O-methyltransferase Val158Met polymorphism on executive function: a meta-analysis of theWisconsin Card Sort Test in schizophrenia and healthy controls. Mol Psychiatry. 2007;12:502-509. (Pubitemid 46656086)
17. Costas J, Sanjuan J, Ramos-Rios R, et al. Heterozygosity at catechol-O-methyltransferase Val158Met and schizophrenia: new data and meta-analysis [published online ahead of print May 20, 2010]. J Psychiatr Res. 2011;45(1):7-14.
18. Bilder R, Volavka J, Lachman H, et al. The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology. 2004;29:1943-1961. (Pubitemid 39486546)
19. Peerbooms OLJ, van Os J, Drukker M, et al. Meta-analysis of MTHFR gene variants in schizophrenia, bipolar disorder and unipolar depressive disorder: evidence for a common genetic vulnerability? Brain Behav Immun. 2011;25(8):1530-1543.
20. Chen J, Lipska BK, Halim N, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet. 2004;75:807-821. (Pubitemid 39390488)
21. Tan H, Callicott J, Weinberger D. Prefrontal cognitive systems in schizophrenia: towards human genetic brain mechanisms. Cogn Neuropsychiatry. 2009;14:277-298.
22. Lahiri DK, Nurnberger JI Jr. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 1991;19:5444.
23. Komossa K, Rummel-Kluge C, Hunger H, et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009;7(4):CD006627.
24. Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263-265. (Pubitemid 40202029)
25. Ehrlich S,Morrow EM, Roffman JL, et al. The COMT Val108/158Met polymorphism and medial temporal lobe volumetry in patients with schizophrenia and healthy adults. Neuroimage. 2010;53(3):992-1000.
26. Roffman JL, Weiss AP, Purcell S, et al. Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. Biol Psychiatry. 2008;63:42-48. (Pubitemid 350234878)
27. Roffman JL, Gollub RL, Calhoun VD, et al. MTHFR 677C Y9 T genotype disrupts prefrontal function in schizophrenia through an interaction with COMT 158Val -> Met. Proc Natl Acad Sci U S A. 2008;105:17573-17578.
28. van Winkel R, Rutten BP, Peerbooms O, et al. MTHFR and risk of metabolic syndrome in patients with schizophrenia [published online ahead of print June 12, 2010]. 2010;121(1-3):193-198.
29. Friso S, Choi SW. Gene-nutrient interactions in one-carbon metabolism. Curr Drug Metab. 2005;6:37-46. (Pubitemid 40277880)